"Mei, J." . "Nixon, A." . "RIV/61988987:17110/12:A13017JD!RIV13-MSM-17110___" . . "Dimopoulos, M. A." . . "1592-8721" . . . "10"^^ . . . . "17110" . . . "[922566B9600D]" . "Lenalidomide, melphalan, and prednisone followed by lenalidomide maintenance improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial" . . . "97" . "Zhang, J." . "Lewis, P." . . "H\u00E1jek, Roman" . "Lenalidomide, melphalan, and prednisone followed by lenalidomide maintenance improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial"@en . . "1"^^ . "I" . "IT - Italsk\u00E1 republika" . "Health-related quality of life; multiple myeloma; lenalidomide; QLQ-C30; QLQ-MY20"@en . "Dec 14" . "Haematologica" . "RIV/61988987:17110/12:A13017JD" . "The MM-015 trial assessed lenalidomide-based therapy on health-related quality of life. Patients completed health-related quality of life questionnaires at baseline, after every third treatment cycle, and treatment end. Health-related quality of life improved in all treatment groups during induction therapy. More patients receiving lenalidomide maintenance achieved minimally important differences (P<0.05 for Physical Functioning). Therefore, lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance improves health-related quality of life in patients with newly diagnosed multiple myeloma."@en . "37"^^ . "The MM-015 trial assessed lenalidomide-based therapy on health-related quality of life. Patients completed health-related quality of life questionnaires at baseline, after every third treatment cycle, and treatment end. Health-related quality of life improved in all treatment groups during induction therapy. More patients receiving lenalidomide maintenance achieved minimally important differences (P<0.05 for Physical Functioning). Therefore, lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance improves health-related quality of life in patients with newly diagnosed multiple myeloma." . . . . "Lenalidomide, melphalan, and prednisone followed by lenalidomide maintenance improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial" . "Petrucci, MT" . . "Kropff, M." . "Delforge, M." . "Palumbo, A." . "Lenalidomide, melphalan, and prednisone followed by lenalidomide maintenance improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial"@en . "146810" .